These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 16182735

  • 1. Malignancies after kidney transplantation.
    Rascente M, Pisani F, Barletta A, D'Angelo M, Giammaria A, Parzanese I, Rizza V, Iaria G, Famulari A.
    Transplant Proc; 2005; 37(6):2529-31. PubMed ID: 16182735
    [Abstract] [Full Text] [Related]

  • 2. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases.
    Baccarani U, Adani GL, Montanaro D, Risaliti A, Lorenzin D, Avellini C, Tulissi P, Groppuzzo M, Currò G, Luvisetto F, Beltrami A, Bresadola V, Viale PL, Bresadola F.
    Transplant Proc; 2006 May; 38(4):1135-7. PubMed ID: 16757287
    [Abstract] [Full Text] [Related]

  • 3. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.
    Saigal S, Norris S, Muiesan P, Rela M, Heaton N, O'Grady J.
    Liver Transpl; 2002 May; 8(5):482-7. PubMed ID: 12004349
    [Abstract] [Full Text] [Related]

  • 4. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.
    Boratyńska M, Watorek E, Smolska D, Patrzałek D, Klinger M.
    Transplant Proc; 2007 Nov; 39(9):2736-9. PubMed ID: 18021973
    [Abstract] [Full Text] [Related]

  • 5. De novo malignancies after renal transplantation--a single-center experience in the Balkans.
    Popov Z, Ivanovski O, Kolevski P, Stankov O, Petrovski D, Cakalaroski K, Ivanovski N.
    Transplant Proc; 2007 Oct; 39(8):2589-91. PubMed ID: 17954184
    [Abstract] [Full Text] [Related]

  • 6. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
    Birkeland SA, Hamilton-Dutoit S, Bendtzen K.
    Transplantation; 2003 Jul 15; 76(1):153-8. PubMed ID: 12865802
    [Abstract] [Full Text] [Related]

  • 7. Renal transplantation in patients with Balkan endemic nephropathy.
    Basic-Jukic N, Hrsak-Puljic I, Kes P, Bubic-Filipi L, Pasini J, Hudolin T, Kastelan Z, Reiner Z, Kordic M, Brunetta B, Juric I.
    Transplant Proc; 2007 Jun 15; 39(5):1432-5. PubMed ID: 17580155
    [Abstract] [Full Text] [Related]

  • 8. Early de novo malignancies after kidney transplantation.
    Veroux M, Puliatti C, Fiamingo P, Cappello D, Macarone M, Puliatti D, Vizcarra D, Gagliano M, Veroux P.
    Transplant Proc; 2004 Apr 15; 36(3):718-20. PubMed ID: 15110643
    [Abstract] [Full Text] [Related]

  • 9. Cancer incidence and survival in kidney transplant patients.
    Navarro MD, López-Andréu M, Rodríguez-Benot A, Agüera ML, Del Castillo D, Aljama P.
    Transplant Proc; 2008 Nov 15; 40(9):2936-40. PubMed ID: 19010153
    [Abstract] [Full Text] [Related]

  • 10. Post-transplant lymphoproliferative disorder following pediatric heart transplantation.
    Mendoza F, Kunitake H, Laks H, Odim J.
    Pediatr Transplant; 2006 Feb 15; 10(1):60-6. PubMed ID: 16499589
    [Abstract] [Full Text] [Related]

  • 11. Long-term kinetics of a T-lymphocytes subset in kidney transplant recipients: relationship with posttransplant malignancies.
    Glowacki F, Al Morabiti M, Lionet A, Labalette M, Provot F, Noel C, Hazzan M.
    Transplant Proc; 2009 Oct 15; 41(8):3323-5. PubMed ID: 19857742
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL.
    Dan Med Bull; 2007 May 15; 54(2):112-39. PubMed ID: 17521527
    [Abstract] [Full Text] [Related]

  • 14. Conversion to rapamycin immunosuppression for malignancy after kidney transplantation.
    Manuelli M, De Luca L, Iaria G, Tatangelo P, Sforza D, Perrone L, Bellini MI, Angelico R, Anselmo A, Tisone G.
    Transplant Proc; 2010 May 15; 42(4):1314-6. PubMed ID: 20534289
    [Abstract] [Full Text] [Related]

  • 15. Risk factors for cardiovascular disease during the first 2 years after renal transplantation.
    Laurés AS, Gómez E, Baltar J, Alvarez-Grande J.
    Transplant Proc; 2005 Nov 15; 37(9):3778-81. PubMed ID: 16386536
    [Abstract] [Full Text] [Related]

  • 16. Development of malignancy following living donor kidney transplantation.
    Nafar M, Einollahi B, Hemati K, Gholi FP, Firouzan A.
    Transplant Proc; 2005 Sep 15; 37(7):3065-7. PubMed ID: 16213306
    [Abstract] [Full Text] [Related]

  • 17. [Incidence of de novo neoplasms after liver transplantation].
    Berenguer M, Prieto M, Bustamante M, Carrasco D, López-Andújar R, Mir J, Berenguer J.
    Med Clin (Barc); 1998 Oct 24; 111(13):481-4. PubMed ID: 9859063
    [Abstract] [Full Text] [Related]

  • 18. Hepatocellular carcinoma in renal transplant recipients.
    Chuang CH, Chien YS, Cheng YT, Chen YT, Hu TH, Hsieh H.
    Transplant Proc; 2008 Sep 24; 40(7):2392-4. PubMed ID: 18790244
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.